Development and validation of the antibody-dependent cellular phagocytosis-based signature: A prognostic risk model of gastric cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new antibody-dependent cellular phagocytosis (ADCP) signature predicts poor prognosis in gastric cancer (GC). This signature is linked to the tumor microenvironment and may guide personalized immunotherapy for GC patients.
Area Of Science
- Oncology
- Immunology
- Cancer Genomics
Background
- Antibody-dependent cellular phagocytosis (ADCP) influences the tumor microenvironment (TME) and cancer therapy.
- No established ADCP-based signature exists for predicting gastric cancer (GC) prognosis.
Purpose Of The Study
- To develop and validate an ADCP-based signature for improved GC prognosis prediction.
- To explore the association between the ADCP signature and the TME.
- To establish a predictive nomogram for GC patient survival.
Main Methods
- Differential expression analysis of ADCP genes.
- Construction and validation of an ADCP-based signature.
- Exploration of signature's association with TME and immune components.
- Development of a predictive nomogram incorporating the signature.
Main Results
- A four-gene ADCP signature (MKNK2, VCAN, LRAT, GNGB) was developed.
- High ADCP scores correlated with unfavorable GC prognosis (p < 0.05).
- The signature associated with immune cells, checkpoints, and pathways (p < 0.05).
- Patients with high ADCP scores showed reduced benefit from immunotherapy.
- A nomogram achieved AUCs of 0.669-0.685 for 1-5 year survival prediction.
Conclusions
- The ADCP-based signature offers a novel approach for GC prognosis.
- This signature may aid in personalized treatment strategies for GC patients.
- Further validation is warranted for clinical application.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.